068270.KO · Celltrion, Inc

-

Please sign in to comment on 068270.KO

1 Comment

Admin

4 years ago

Celltrion, Inc is currently in a long term downtrend where the price is trading 11.1% below its 200 day moving average.

From a valuation standpoint, the stock is 161.5% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 22.4.

Celltrion, Inc's total revenue rose by 30.3% to $499B since the same quarter in the previous year.

Its net income has increased by 2.7% to $98B since the same quarter in the previous year.

Finally, its free cash flow grew by 390.3% to $155B since the same quarter in the previous year.

Based on the above factors, Celltrion, Inc gets an overall score of 3/5.

Exchange	KO
CurrencyCode	KRW
ISIN	KR7068270008
Sector	Healthcare
Industry	Biotechnology

Beta	0.5
Market Cap	35T
PE Ratio	None
Target Price	235250
Dividend Yield	0.4%

ABOUT

Celltrion, Inc

Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets biopharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P44 that is in phase 3 clinical trial for the treatment of multiple myeloma; CT-P51, which is in phase 3 clinical trial for the treatment of Melanoma, lung cancer; CT-P53, which is in phase 3 clinical trial for the treatment of multiple sclerosis; and CT-P55 that is in phase 3 clinical trial for the treatment of Psoriasis. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.

068270.KO · Celltrion, Inc

-

Celltrion, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Celltrion, Inc using a moving average strategy